Takeda’s Global Ambitions Focus On Crohn’s, Cancer – And Churn
Three product launches in U.S. last year, including Entyvio, showcase its expansion strategy, but first non-Japanese CEO could be biggest shift for firm.
You may also be interested in...
District court finds formulation patent covering Takeda’s top drug is obvious in light of prior art, opening product up to generic competition in 2017.
European biotech executives, entrepreneurs and investors are much more optimistic today about the sector’s growth prospects than just a few years ago – that’s despite lingering negatives like the region’s small number of mid-sized companies, a lack of investors willing to finance beyond seed and Series A rounds, and the relative dearth of executive talent.
Takeda’s beleaguered Nesina (alogliptin) becomes the fourth DPP-4 inhibitor approved by FDA for diabetes; it remains to be seen whether the drug can find its place in a highly competitive space that continues to be controlled by Merck’s first-to-market blockbuster Januvia.